HRT and osteoporosis drugs work differently and have different risk profiles. Estrogen prevents bone loss by restraining osteoclast activity, and its bone-protective effect is well established. Bisphosphonates (Fosamax) and denosumab (Prolia) directly inhibit bone resorption but carry risks including jaw osteonecrosis, atypical fractures, and (for Prolia) rebound bone loss on discontinuation. For perimenopausal and early postmenopausal women, HRT addresses the root cause of bone loss while also treating other menopause symptoms.
Bone loss accelerates during menopause because estrogen is a key regulator of bone remodeling. Estrogen restrains osteoclasts (cells that break down bone) and supports osteoblasts (cells that build bone). When estrogen declines, bone breakdown outpaces bone formation, leading to osteopenia and osteoporosis.
HRT replaces the missing estrogen, directly addressing the cause of menopausal bone loss. It is effective at preventing fractures and is the only treatment that also addresses the other symptoms of menopause. For women under 60 or within 10 years of menopause, HRT is considered first-line by many bone health experts.
Bisphosphonates (Fosamax, Actonel, Boniva) work by killing osteoclasts, which slows bone breakdown but also impairs the normal remodeling process. Long-term use (beyond 5 to 10 years) is associated with atypical femoral fractures and osteonecrosis of the jaw — rare but serious complications.
Denosumab (Prolia) is a biologic that also inhibits bone resorption. It is effective but has a significant drawback: stopping Prolia causes rapid rebound bone loss, sometimes worse than pre-treatment levels. Patients who start Prolia are essentially committed to staying on it or transitioning carefully to another agent.
Neither bisphosphonates nor Prolia address the underlying estrogen deficiency or treat any other menopause symptoms. They are appropriate for women who cannot or choose not to take HRT, or for women past the recommended HRT initiation window.
At Viking, bone health is part of the comprehensive approach to hormone optimization, and your provider can discuss whether HRT provides adequate bone protection for your situation.